Data / Form D filings / DEXCOM INC
DEXCOM INC: Form D filings
DEXCOM INC, a biotechnology company in San Diego, CA, filed 3 Form D notices with the SEC between 2012 and 2016. The latest, on May 18, 2016, reports $7.2 million sold of a $7.2 million offering to 2 investors.
Find out what DEXCOM INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6340 SEQUENCE DRIVE, San Diego, CA, 92121
- Phone
- (858) 200-0200
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1093557
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2016 | New notice | $7,225,664 | $7,225,664 | $0 | 2 | May 2, 2016 | sec.gov |
| Apr 12, 2012 | Amendment | $7,646,504 | $3,964,019 | $3,682,485 | 30 | Mar 16, 2012 | sec.gov |
| Apr 12, 2012 | New notice | $7,646,504 | $3,964,019 | $3,682,485 | 30 | Mar 16, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Richard K. Doubleday | Executive Officer | |
| Eric T. Topol | Director | |
| Barbara E. Kahn | Director | |
| Steven R. Pacelli | Executive Officer | |
| Jonathan T. Lord | Director | |
| Jeffrey D. Moy | Executive Officer | |
| Nicholas H. Augustinos | Director | |
| Terrance H. Gregg | Executive Officer, Director | |
| Jorge R. Valdes | Executive Officer | |
| John D. Lister | Executive Officer | |
| Jess R. Roper | Executive Officer | |
| Andrew K. Balo | Executive Officer | |
| Jay S. Skyler | Director | |
| Kevin Sayer | Executive Officer, Director | |
| Steven R. Altman | Director | |
| Mark S. Foletta | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
Every Form D from the week of May 16, 2016 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what DEXCOM INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.